Bevacizumab

Canadian Cancer Patients Have New Affordable Treatment Option

Monday, September 27, 2021 - 2:02pm

The company, a pioneer and leader in oncology biosimilars in Canada, recently received approval from Health Canada for its first therapeutic product.

Key Points: 
  • The company, a pioneer and leader in oncology biosimilars in Canada, recently received approval from Health Canada for its first therapeutic product.
  • Bambevi ( bevacizumab) is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer.
  • This approval, coupled with well-established Apobiologix supportive care products, further enables Apobiologix to deliver on its mission to transform access to affordable therapies in oncology and beyond.
  • These products encourage the body's production of white blood cells, which helps to fight infection in patients undergoing certain cancer treatments, such as chemotherapy and radiation.

AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

Monday, September 27, 2021 - 1:00pm

The data was announced as a keynote presentation at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting on September 25-29, 2021.

Key Points: 
  • The data was announced as a keynote presentation at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting on September 25-29, 2021.
  • The scientific presentation entitled: Taletrectinib (AB-106): Preliminary results from TRUST, Phase trial of a new generation of potent ROS1/NTRK inhibitors in ROS1-positive non-small cell lung cancer (NSCLC), summarized preliminary data from an ongoing Phase trial of taletrectinib (NCT04395677).
  • Our team is focused on completing patient enrollment for our Phase TRUST trial, said Bing Yan, MD, Co-founder and Chief Medical Officer at AnHeart Therapeutics.
  • The interim data presented builds a strong foundation for our ongoing global pivotal taletrectinib clinical program.

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit

Sunday, September 26, 2021 - 3:12am

Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.

Key Points: 
  • Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.
  • The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the 12th time this year.
  • The CEA/ CD3 bispecific antibody BA1202 is the first clinical candidate developed on the leading bispecific T-cell Engager platform.
  • Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform.

Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Tuesday, September 21, 2021 - 1:05pm

In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .
  • A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Outlook Therapeutics website ( outlooktherapeutics.com ) and accessible for 90 days following the event.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway.

New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer

Monday, September 20, 2021 - 2:05pm

Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.

Key Points: 
  • Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.
  • IMpower010 shows how, for the first time, a cancer immunotherapy may help many of these patients live longer without their disease returning.
  • The data presented at ESMO and WCLC further contribute to our understanding of Tecentriq in this treatment setting.
  • Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in markets around the world.

Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

Monday, September 20, 2021 - 1:00pm

The trial is being conducted under a clinical collaboration with F. Hoffman La-Roche (Roche).

Key Points: 
  • The trial is being conducted under a clinical collaboration with F. Hoffman La-Roche (Roche).
  • The initiation of this randomized TPST-1120 study in collaboration with Roche marks significant progress in the advancement of the Tempest clinical pipeline, said Sam Whiting, MD, Ph.D., chief medical officer of Tempest.
  • The Tempest team looks forward to further evaluation of TPST-1120 in this randomized combination in the first-line treatment of patients with HCC.
  • Under the terms of the collaboration agreement, Roche will manage the study operations for this global, multicenter trial.

Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

Sunday, September 19, 2021 - 4:30pm

Interim results from the innovaTV 205 study show the potential for tisotumab vedotin to treat these patients with encouraging response rates in combination with carboplatin and also in combination with pembrolizumab.

Key Points: 
  • Interim results from the innovaTV 205 study show the potential for tisotumab vedotin to treat these patients with encouraging response rates in combination with carboplatin and also in combination with pembrolizumab.
  • Based on these results from the innovaTV 205 study, we also plan to evaluate tisotumab vedotin further in various combinations in first-line metastatic or recurrent cervical cancer.
  • We recognize the need for new therapies for patients with cervical cancer globally and are committed to advancing the tisotumab vedotin development program.
  • Additionally, Seagen and Genmab presented data from dose-escalation cohorts of the innovaTV 205 study at the 2021 International Gynecologic Cancer Society (IGCS) Annual Meeting held August 30-September 2, 2021.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

Saturday, September 18, 2021 - 2:05pm

These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.

Key Points: 
  • These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.
  • Cervical cancer is the fourth most commonly diagnosed cancer in women and the fourth leading cause of cancer-related death in women globally.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Legend Capital Led a New Round of Investment of Etana

Tuesday, September 14, 2021 - 12:42am

HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).

Key Points: 
  • HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).
  • Hong Tan, Managing Director of Legend Capital, said "We appreciate Etana's vision to provide Indonesia with cost-effective biopharmaceuticals.
  • Legend Capital is an independent professional venture capital company under Legend Holdings.
  • Its core business is positioned at the initial stage of venture capital and expansion stage growth investment.

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference

Monday, September 13, 2021 - 1:05pm

ONS-5010 has been rigorously tested to support our efforts to provide the first approved ophthalmic formulation of bevacizumab, said C. Russell Trenary III, President and Chief Executive Officer, Outlook Therapeutics.

Key Points: 
  • ONS-5010 has been rigorously tested to support our efforts to provide the first approved ophthalmic formulation of bevacizumab, said C. Russell Trenary III, President and Chief Executive Officer, Outlook Therapeutics.
  • Outlook Therapeutics wet AMD ONS-5010 clinical program for the planned BLA submission consists of three clinical trials, NORSE ONE, NORSE TWO, and NORSE THREE, all of which have now been completed.
  • Most recently, Outlook Therapeutics reported positive topline data from its NORSE TWO pivotal Phase 3 clinical trial.
  • Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.